Through this new financing of € 150 m, the EIB reiterates its supports to Evotec, a company that it already supported in 2017 with a financing of € 75 m. This new agreement is to be signed in Toulouse during a visit of the site on which the new biologics manufacturing facility will be built.
As a life science company focused on research, development, and manufacturing of novel precision medicines, Evotec aims to create global access to first- and best-in-class therapeutics. The Company works in partnerships with all Top 20 Pharma and more than 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders to achieve a better disease understanding and deliver novel and more targeted therapeutic approaches regardless of therapeutic modality.
The EIB funding specifically supports Evotec’s business strategy through a unique, innovative and flexible financing structure including a low fixed interest rate plus a reward-sharing component for the EIB. The loan with a total volume of up to € 150 m will be invested over a period of three years and each tranche will mature seven years after draw down. Evotec will use the financing to fund its internal R&D activities, equity investments, as well as the new biologics manufacturing facility, J.POD® Toulouse, France (EU).
By providing funds for proprietary research in a broad range of currently underserved therapeutic areas, the EIB financing will enable Evotec to initiate additional innovative R&D activities as well as create new partnering opportunities, leveraging its precision medicine platforms. Since 2016, Evotec has also been driving medical innovation as an operational investor in early-stage biotechnology companies – spin-offs, joint ventures as well as independent start-ups. The EIB financing will enable Evotec to further broaden its portfolio, which currently spans more than 90 active projects across more than 30 companies worldwide.
On the manufacturing side, the EIB financing will support the construction of a highly innovative facility for continuous biologics manufacturing at Evotec’s Campus Curie. J.POD® Toulouse, France (EU) is the second facility of its kind and the first one on European ground. It will bring advanced biomanufacturing to the EU and will deliver much-needed clinical and commercial manufacturing capacity for biologics. The construction of J.POD® Toulouse, France (EU) is also supported by the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture as well as Toulouse Métropole with up to € 50 m.
Enno Spillner, Chief Financial Officer of Evotec, commented: “We are excited to enter into this second financing agreement with the European Investment Bank. By funding transformational projects in key areas of public interest, EIB is an important driver of innovation in the EU. We are honoured and excited to be able to create new R&D partnering opportunities and establish Europe’s first J.POD® biologics manufacturing plant through the innovative financing model from the EIB at highly attractive terms. This new agreement with EIB builds on the excellent relationship we have developed as part of the first financing agreement entered in 2017. The EIB’s support will help us deliver on our mission ‘Together for Medicines that Matter’.”
EIB Vice President Ambroise Fayolle said: “We are very pleased to support Evotec's investments in research, development and innovation with this second financing agreement signed with the European Investment Bank. It demonstrates our commitment to supporting European biotech companies at the cutting edge of innovation in a sector marked by very strong global competition. This EIB investment will also have a significant impact on activity in the Toulouse region, as it will help to finance a 12,000 square metre plant that will create more than 200 highly skilled jobs.”
The transaction is going to be signed by Members of Evotec’s Management Board and the Vice President of the European Investment Bank, Ambroise Fayolle, during a ceremony on Evotec’s Campus Curie in Toulouse today. This financing agreement, as well as a previous loan of € 75 m by the EIB in 2017, has been developed in cooperation with kENUP Foundation, an NGO supporting innovation in Europe.